You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Managing the Care of Ovarian Cancer With Poly(ADP-Ribose) Polymerase Inhibitors: A Managed Care Approach 

  • Authors: Donyika Joseph, PharmD, BCOP; Laura R. Bobolts, PharmD, BCOP; Kathleen Moore, MD, MS
  • CME / ABIM MOC / CE Released: 11/21/2022
  • Valid for credit through: 11/21/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    IPCE: 0.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for Academy of Managed Care Pharmacy (AMCP) members, Medscape registered oncology pharmacist members, PowerPak pharmacist members, Medscape registered oncologist members, and other physicians.

The goal of this 30-minute video activity is to educate managed care pharmacists, clinical pharmacists in different practice settings, and physicians about the clinical utility of PARP inhibitors in advanced ovarian cancer (OC); review considerations important in delivering evidence-based, cost-effective therapy in OC; and summarize the role of managed care pharmacists in coordinating care with the interprofessional team to achieve optimal patient outcomes.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical role of poly(ADP-ribose) polymerase (PARP) inhibitors in the management of advanced OC
    • Pharmacoeconomic data on PARP inhibitor therapy for OC
  • Demonstrate greater confidence in their ability to
    • Make recommendations for optimizing PARP inhibitor therapy in the management of patients with advanced OC  
    • Use an interprofessional approach to improve clinical and quality-based outcomes in patients with OC receiving PARP inhibitor therapy 


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Donyika Joseph, PharmD, BCOP

    Clinical Pharmacy Specialist
    Gynecology Oncology
    Division of Pharmacy
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Donyika Joseph, PharmD, BCOP, has no relevant financial relationships.

  • Laura R. Bobolts, PharmD, BCOP

    SVP, Clinical Strategy and Growth
    OncoHealth
    Atlanta, Georgia

    Disclosures

    Laura R. Bobolts, PharmD, BCOP, has no relevant financial relationships.

  • Kathleen Moore, MD, MS

    Professor, Section of Gynecologic Oncology
    Virginia Kerley Cade Chair
    in Developmental Therapeutics
    Director, Oklahoma TSET Phase I Program
    OU Stephenson Cancer Center
    Oklahoma University College of Medicine
    Oklahoma City, Oklahoma

    Disclosures

    Kathleen Moore, MD, MS, has the following relevant financial relationships:
    Consultant or advisor for: Addi; Alkermes; Aravive; AstraZeneca; Blueprint; Bristol Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Genentech/Roche; GlaxoSmithKline/Tesaro; Hengrui; I-Mab; ImmunoGen; InxMed; Lilly; Merck; Mereo; Mersana Therapeutics; Myriad; Novartis; OncoNova; OncXerna; Sankyo; VBL Therapeutics; Verastem Oncology
    Research funding from: GlaxoSmithKline; Lilly; Merck; PTC Therapeutics; Verastem Oncology
    Monetary compensation for an executive role from: GOG Partners

Editors

  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC

    Disclosures

    Amy Furedy, RN, OCN, has no relevant financial relationships.

  • Yoji Yamaguchi, MA, ELS

    Scientific Content Manager, Medscape, LLC

    Disclosures

    Yoji Yamaguchi, MA, ELS, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Developed through a partnership between Medscape and Academy of Managed Care Pharmacy.



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-22-247-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Managing the Care of Ovarian Cancer With Poly(ADP-Ribose) Polymerase Inhibitors: A Managed Care Approach 

Authors: Donyika Joseph, PharmD, BCOP; Laura R. Bobolts, PharmD, BCOP; Kathleen Moore, MD, MSFaculty and Disclosures

CME / ABIM MOC / CE Released: 11/21/2022

Valid for credit through: 11/21/2023

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.